Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ALGN · against 160 other Healthcare companies of similar size
Ranked #33 of 161 · scores higher than 78% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 70–79, including ALGN · Click a bar to see the companies
Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | ALGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 160 reported | 3.8% | 2.6% | 69% | 30% | |
| EBITDA yieldHigher is better · 160 reported | 9.5% | 4.7% | 84% | 50% | |
| Free cash flow yieldHigher is better · 95 reported | 5.9% | 2.3% | 86% | 20% | |
| Book yieldHigher is better · 159 reported | 39.2% | 18.6% | 76% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 4 | 21.5B USD | 95 | 60 | |
| 30 | 13.3B USD | 73 | 59 | |
| 30 | 18.5B USD | 73 | 54 | |
| 33 | 1.21T JPY (≈$8.2B) | 72 | 74 | |
| 33 | 47.8B HKD (≈$6.1B) | 72 | 60 | |
| 33 | 10.8B USD | 72 | 54 | |
| 33 | 14.9B USD | 72 | 65 | |
| 37 | 47.8B HKD (≈$6.1B) | 71 | 58 | |
| 37 | 1.17T JPY (≈$8.0B) | 71 | 58 | |
| 37 | 975.0B INR (≈$11.7B) | 71 | 65 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score